Figure 4.

Characteristics of differentiated neuronal-like cells by BMSCs after 2 weeks of citalopram treatment.

Immunostaining showed that rates of nestin, MAP-2, β-tubulin and neurofilament L positive staining significantly increased compared to that in control (*P < 0.05) (A).rentiated by BMSCs in the presence of RA and citalopram compared to the only dimethyl sulfoxide pre-treatment (*P≤ 0.05) (B). Cell proliferation assays for neuronal-like cells with and without citalopram. Cumulative population doubling level of cells in cultures with and without citalopram. Cumulative population doubling level of citalopram-treated cells were significantly increased from day 15 until day 21 compared with RA-treated cells (*P < 0.05) (C). (A–C) Data are expressed as mean ± SEM. One-way analysis of variance (ANOVA) and two-tailed Student's t-test were used to analyze data. Each experiment was performed in triplicate. BMSCs: Bone marrow mesenchymal stem cells; MAP-2: microtubule-associated protein 2; GFAP: glial fibrillary acidic protein; RA: retinoic acid.